Quality assessment of diagnostic before-after studies: development of methodology in the context of a systematic review by Catherine A Meads & Clare F Davenport
BioMed Central
BMC Medical Research 
Methodology
ssOpen AcceResearch article
Quality assessment of diagnostic before-after studies: development 
of methodology in the context of a systematic review
Catherine A Meads*† and Clare F Davenport†
Address: Unit of Public Health, Epidemiology and Biostatistics, University of Birmingham, Birmingham, UK
Email: Catherine A Meads* - c.a.meads@bham.ac.uk; Clare F Davenport - c.f.davenport@bham.ac.uk
* Corresponding author    †Equal contributors
Abstract
Background: Quality assessment tools for primary studies of test accuracy are relatively well
developed, although only one is validated (QUADAS), but very little work has been done to
develop tools to quality-assess studies evaluating the impact of diagnostic testing on management
of patients (diagnostic or therapeutic yield). The recent draft NICE Guide to the Methods of
Technology Appraisal (2007) suggests QUADAS "as a useful starting point for appraising studies
that evaluate the sensitivity and specificity of a test" but does not mention how to quality assess
diagnostic or therapeutic yield studies, in particular diagnostic before-after studies. In the context
of undertaking a rapid systematic review of structural neuroimaging in psychosis for NICE, we
describe the modifications that we made to QUADAS, our experience of this in practice and in
relation to published theory on diagnostic or therapeutic yield studies.
Methods: The QUADAS tool was assessed for use in the review by two systematic reviewers with
in-depth knowledge of the clinical area being reviewed and the types of studies being found in the
searches that could answer the clinical question. Modifications were made following discussion as
considered appropriate.
Results: Two QUADAS questions were removed altogether and. four additional questions were
developed to capture additional quality issues not addressed by QUADAS. However, the
developed checklist only partially helped to discern implications of the study designs on the results
given.
Conclusion: The division between topic-specific and more generic quality items of relevance to
diagnostic before-after studies is important. With more time, further work could have been done
to create a better quality assessment tool, for example by incorporating some of the issues
mentioned in previous work in this area. This paper is a discussion around quality assessment and
is intended to offer insights into the types of issues that should be assessed. A quality assessment
tool for diagnostic before-after studies that incorporates items from QUADAS and published
theory needs to be further developed and validated.
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The evaluation of diagnostic technologies includes assess-
ment of test accuracy and clinical, process or economic
outcomes following testing (see additional file 1)[1]. The
impact of a test depends on a variety of factors in addition
to test accuracy including; interpretation of tests results,
the possibility that the new information does not contrib-
ute sufficiently to cross a treatment threshold, clinician
awareness of availability of cost-effective treatments, lack
of patient access to treatments, acceptability of treatments
to patients and the possibility that the patient is already
receiving optimal care[2].
Once test results arrive, clinicians use the information to
make categorise patients into those with and those with-
out disease, known as the diagnostic yield, and then deci-
sions about treatment required – therapeutic yield[1] (see
additional file 1). Diagnostic and therapeutic yield should
be considered separately from the accuracy of the test. For
example, a test could be 100% sensitive and 100% specific
but may not have a high therapeutic yield for a variety of
reasons listed in the previous paragraph.
Study designs that may be employed for evaluations of
diagnostic and therapeutic yield include randomised con-
trolled trials, or non-randomised experimental or obser-
vational studies. Randomised trials may be impractical
due to large sample size requirements,[1] the speed of
technological advances in diagnostics that risks trial
results being obsolete and ethical considerations arising
from the potential to deny patients beneficial treatments.
An observational study design which allows for evalua-
tion of diagnostic or therapeutic yield is the diagnostic
before-after study, (see additional file 2). For this study
design in its most basic form, a group of patients undergo
an existing test or battery of tests and the therapeutic strat-
egy is noted, depending on the test results. They then have
the new test to be evaluated and any change of diagnosis
or treatment strategy is noted and compared. The design
can be elaborated to include measurement of test accuracy
if the new test is not the reference standard, and assess-
ment of patient outcomes following treatment. Diagnos-
tic before-after studies may be retrospective or prospective
in contrast to the temporal relationship traditionally
implied by before-after evaluation studies.
Diagnostic before-after studies are subject to a number of
limitations[2] such as discrepancies between stated clini-
cal assessment and actual clinical action, and possible
subconscious bias about the benefits of the new technol-
ogy – a clinician may delay making a definitive diagnosis
if they know that another test is going to be performed.
Also there can be no direct comparison of patient out-
comes because all have had the new test. However some
of the limitations can be overcome by careful planning
and conduct of the study. For example using a prospective
design may ameliorate review bias, and independently
reviewing pre-and post test clinical assessment and strictly
adhering to a study protocol may ameliorate discrepan-
cies between stated clinical assessment and actual clinical
action.
Observational studies, such as diagnostic before-after
studies, are easier and quicker to conduct than RCTs[3]. In
addition it is considered that diagnostic before-after stud-
ies tend to be biased in favour of new interventions so
when no benefit is found, it is unlikely that a stronger
study design on the same question, such as an RCT, will
find a benefit[2]. Therefore despite limitations, diagnostic
before-after studies may have a role in evaluating thera-
peutic impact of diagnostic tests.
This paper discusses an example of the use of diagnostic
before-after studies to evaluate the effectiveness of struc-
tural neuro-imaging in psychosis in the context of under-
taking a health technology assessment for the NICE
technology appraisals programme in the UK. The system-
atic review underpinning this methodological paper is
published as an HTA monograph[4]. The decision prob-
lem for the systematic review underlying this work was to
evaluate the added value of structural neuro-imaging with
CT or MRI compared to current practice alone. Current
practice was defined as any test(s) or investigation(s), or
any combination of tests that would be carried out as part
of the initial care of a psychotic patient to identify brain
lesions in two patient groups – acutely psychotic patients
and psychotic patients who are treatment-resistant or
deteriorating despite treatment[4]. This decision problem
can be conceptualised as a before and after comparison of
two diagnostic strategies – current practice only and cur-
rent practice with CT and/or MRI (see additional file 3)
where CT and MRI are considered reference standards for
the pathology investigated (target disorders). However,
unlike most diagnostic yield studies where a single target
condition is investigated, this review had several target
conditions i.e. any organic disorder with the potential to
cause psychosis as well as any treatable organic condition
that may coexist with psychosis; including cerebrovascu-
lar accident (CVA), various vascular disorders and brain
tumours. The best structural neuroimaging method to
determine the presence or absence of these conditions var-
ies depending upon the condition. For example, CT is
considered better than MRI for diagnosing calcification,
whereas MRI is the gold standard for the diagnosis of
space occupying lesions. For the purposes of this review
CT and/or MRI were considered reference standard tests
for the pathologies being investigated and so additional
assessment of test accuracy was not considered a necessary
component of included studies. The key question to bePage 2 of 8
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tion of neuroimaging would affect diagnostic yield,
patient management (therapeutic yield) and ultimately
patient outcomes.
In this situation an RCT for diagnostic or therapeutic yield
would not be useful because multiple conditions were
being sought. If patient outcomes such as health-related
quality of life and mortality due to undetected treatable
conditions were the outcomes measured, the sample size
would need to be massive. Therefore the most likely
design that would be found in a systematic review would
be a diagnostic before-after study.
In this context it is important to know some information
about psychosis in order to appreciate the clinical sce-
nario. In 2005–6 there were 41,600 NHS finished epi-
sodes and 2,617,500 bed days in England due to
psychotic illnesses[5]. Psychosis secondary to a brain
tumour is rare. The prevalence of brain tumours in psychi-
atric patients has been estimated in a review of cross sec-
tional studies of prevalent cases to be approximately 1.2%
(using CT scan). However this does not distinguish
between psychotic patients with coincidental brain
tumours and patients with brain tumours causing their
psychotic symptoms[6]. Psychotic patients can develop
additional pathology at any time during their life. Struc-
tural neuroimaging (MRI and CT scanning) allows non-
invasive visualisation of anatomical structure of the brain
in order to assist in the diagnosis of intracranial pathol-
ogy. As it has been estimated that between 4.3–10% of
patients have psychological reactions sufficiently severe to
require that MRI has to be modified, postponed or can-
celled, it is important to know whether subjecting psy-
chotic patients to this procedure is clinically warranted[7].
When conducting the systematic review, we discovered
that there was no existing quality assessment tool for diag-
nostic before-after studies. Therefore, we had to modify a
validated quality assessment tool for diagnostic accuracy
studies. We describe the modifications that we made to
the QUADAS[8] tool in relation to published theory on
diagnostic or therapeutic yield studies[2,3] and our expe-
rience of using the modified tool in practice.
Standard systematic review methods were used to find
suitable studies to answer the clinical question. The inclu-
sion criteria were any design that gave diagnostic or ther-
apeutic yield, including prospective or retrospective
diagnostic before-after studies, reporting the additional
diagnostic benefit of structural MRI, CT or combinations
of these in patients with psychosis compared to any cur-
rent standard practice of diagnostic workup without struc-
tural neuroimaging. An added complication was whether
there were any symptoms and signs of a space occupying
lesion or not in patients in the included studies. In the
included studies, diagnostic tests conducted before or in
addition to structural neuroimaging were often not
detailed well but, when described, were a variety of medi-
cal and psychiatric history, physical and neurological
examinations, biochemical tests, blood tests, toxicological
screens, mental state examinations, EEG and psychiatric
rating scales. Only studies reporting clinically relevant
outcomes were included in the review, such as the propor-
tion of patients with scans identifying pathology that
would influence patient treatment (therapeutic yield) and
patient outcomes that were not suspected from history
and/or physical examination.
Standard systematic review methods include quality
assessment of included studies. Quality assessment tools
for primary studies of test accuracy are relatively well
developed,[8] although only one is validated – QUA-
DAS[8]. Recent draft NICE Guide to the Methods of Tech-
nology Appraisal (2007) suggests the QUADAS quality
assessment tool "as a useful starting point for appraising
studies that evaluate the sensitivity and specificity of a
test" but no guidance is provided on quality assessment of
diagnostic before-after studies. This lack of a validated
quality assessment tool appears not to have been noticed
up to now, perhaps because there are very few systematic
reviews of diagnostic or therapeutic yield studies. How-
ever, it is likely that in the future NICE will be appraising
more devices and diagnostic tests (Personal Communica-
tion, Carole Longson, NICE, December 2008).
Methods
A pragmatic decision was made to use QUADAS and
adapt it for diagnostic before-after studies. The fourteen
QUADAS questions (see table 1) were assessed by two
experienced systematic reviewers independently for
appropriateness, ease of use and whether the tool would
assess the desired qualities and have discriminant ability.
This was assessed qualitatively using individual judge-
ment as there were no objective criteria to use. The two
reviewers then met to agree which questions to use, how
to adapt them and whether additional questions were
required. The adapted checklist was piloted on a selection
of studies to dermine whether it had reasonable perform-
ance characteristics to distinguish between studies, prior
to full data extraction and quality assessment.
For the purpose of this quality assessment the 'before'
diagnostic strategy was considered the index test as
referred to in QUADAS and the 'after' diagnostic strategy
included CT/MRI and was considered to be a reference
standard for structural organic pathology where a refer-
ence standard is defined as the best test practically availa-
ble approximating to a final diagnosis.Page 3 of 8
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The original QUADAS checklist and the modified check-
list used for quality assessment in the technology
appraisal can be seen in Table 1. The changes from the
original QUADAS checklist are described and explained
below.
Two items were deleted altogether from the original QUA-
DAS checklist – item 3 and item 7. Item 3 ("Is the refer-
ence standard likely to classify the target condition
correctly?") was considered redundant because it was pre-
sumed in all cases that the reference test (CT or MRI)
would classify the target condition correctly. All included
studies had to use CT or MRI so Item 3 would not distin-
guish one study from another within the systematic
review.
Item 7 ("Was the reference standard independent of the
index test (i.e. the index test did not form part of the ref-
erence standard)?") was also considered redundant
because in diagnostic before – after tests the 'after' diag-
nostic strategy (referred to here as the reference test) nec-
essarily incorporated the 'before' component (referred to
here as the index test), ie patients would not get CT/MRI
alone.
Table 1: Original QUADAS items and additional questions used in the neuroimaging review.
Original QUADAS item Additions for the structural neuroimaging review
1. Was the spectrum of patients representative of the patients who will 
receive the test in practice?
2. Were selection criteria clearly described? A. Were patients recruited consecutively?
3. Is the reference standard likely to correctly classify the target 
condition?
Removed for the neuro-imaging review
4. Is the time period between reference standard and index test short 
enough to be reasonably sure that the target condition did not change 
between the two tests?
5. Did the whole sample or a random selection of the sample, receive 
verification using a reference standard of diagnosis?
6. Did patients receive the same reference standard regardless of the 
index test result?
7. Was the reference standard independent of the index test (the index 
test did not form part of the reference standard)?
Removed for the neuro-imaging review
8. Was the execution of the index test described in sufficient detail to 
permit replication of the test?
9. Was the execution of the reference standard described in sufficient 
detail to permit replication of the test?
D. Who performed the clinical evaluation and image analysis?
10. Were the index test results interpreted without knowledge of the 
results of the reference standard?
C. Was the study and/or collection of clinical variables conducted 
prospectively?
11. Were the reference standard results interpreted without knowledge 
of the results of the index test?
12. Were the same clinical data available when test results were 
interpreted as would be available when the test is used in practice?
13. Were uninterpretatable/intermediate test results reported?
14. Were withdrawals from the study explained? B What was the explanation for patients who did not receive CT or 
MRI?
*Index test – tests before MRI/CT, Reference test – MRI/CTPage 4 of 8
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questions to the QUADAS checklist: These extra questions
were developed using an established quality assessment
development guide[9].
A. Were patients recruited consecutively?
This question was added because items 1 and 2 on the
QUADAS checklist refer to issues of sample selection but
consecutive recruitment is not explicitly mentioned. Con-
secutive recruitment is important to prevent bias in the
selection of patients going into the study.
B. What was the explanation for patients who did not 
receive CT or MRI?
This question was added because although Item 14 on the
QUADAS checklist is concerned with whether an explana-
tion for withdrawals from the study was given, it does not
include documentation of reasons. For this review it was
important to distinguish between the studies where
patients were withdrawn at the start of the study because
they refused consent and those studies with patients who
had consented but CT/MRI results were not presented,
possibly because the scan results had been lost. It also
highlighted studies where patients could not tolerate the
procedure, particularly for MRI scanning.
C. Was the study and/or collection of clinical variables 
conducted prospectively?
QUADAS does not address study design explicitly
although items 10 and 11 capture bias that may be intro-
duced by a retrospective versus a prospective study design.
It was decided for the purposes of this review that it was
important to know whether the study was a retrospective
chart review with possible bias in the selection of patients,
results of scans and treatment decisions.
D. Who performed the clinical evaluation and image 
analysis?
Items 8 and 9 on the QUADAS checklist are concerned
with replication of the index and reference test. However
details of their conduct are not required for completion of
the checklist. For the neuro-imaging review test conduct
was important because of the subjective nature of inter-
pretation. It is likely that there might be different results
of the scan was read by a radiologist compared to a psy-
chiatrist.
In summary, although QUADAS may implicitly address
most of these issues of validity, for the purposes of this
review of diagnostic before-after studies we decided it was
necessary to record the presence of absence of these char-
acteristics explicitly.
Application of the checklist to the 24 diagnostic before-
after studies included in the systematic review was suc-
cessful in identifying differences in study conduct and
quality[8]. Following tabulation of quality criteria in the
systematic review, using the modified QUADAS checklist,
possible threats to study validity were used to guide inter-
pretation of results and future research recommendations.
However, the developed checklist did not lead to that
much greater insight into the relationship between poten-
tial threats to study validity identified by the checklist and
the direction of results of the studies.
Discussion
The HTA found that structural neuroimaging identified
little to influence patient management that was not sus-
pected from medical history and/or physical examination.
NICE guidance from this appraisal states the following
"Structural neuroimaging, using methods called magnetic
resonance imaging (MRI) or computed axial tomography
(CT) scanning, is not recommended for use routinely to
examine all people who have had a first episode of psy-
chosis[10]."
Quality assessment using our checklist helped to assess
the included studies and drive report conclusions. It
helped to identify the extent of poor reporting of most of
the studies and drew attention to important omissions.
For example, it helped focus on the details of 'index test'
assessments. These were often poorly reported in the
included studies and it was frequently not clear what
other assessments had been made in addition to scanning.
Because of the checklist we were able to offer a consistent
and transparent assessment of quality of the included
studies.
However, our checklist did not allow us to make a clear
distinction between test results and the contribution they
made to the subsequent diagnosis. For example, some of
the studies appeared to have interpreted scan results with-
out knowledge of other assessments, some had other
results available when interpreting the scan results but for
most studies it was not clear whether the scan results had
been interpreted without knowledge of the results of other
assessments. In most cases it was not possible to tell
whether the same clinical results were available when test
results were interpreted as would be available in practice.
It was also unclear in most studies how the scan results
had changed diagnosis. On the one hand, this issue is to
do with blinding of test interpretation, but on the other
hand, it is about the complex and often subconscious
nature in which diagnoses are made[11] and how we
assess the contribution of a test result to obtain a final
diagnosis.
We did not define acceptable variation in the definition of
the reference standard beforehand. As a result, there was
some confusion as to whether the reference standard inPage 5 of 8
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QUADAS item (outcome = test accuracy) Methodological issues raised by Guyatt 
(outcome = therapeutic impact)
1. Was the spectrum of patients representative of the patients who will 
receive the test in practice?
The specific clinical indication for performing the test should be clear.
2. Were selection criteria clearly described? Bias may be introduced if the sample does not comprise consecutive 
patients presenting with a specific clinical problem
3. Is the reference standard likely to correctly classify the target 
condition?
Not all before after studies evaluate a reference standard as the after 
test. Where the after test is not a recognised reference standard for the 
target disease full delineation of the impact of test errors requires 
evaluation of all study subjects with a reference standard.
4. Is the time period between reference standard and index test short 
enough to be reasonably sure that the target condition did not change 
between the two tests?
Not addressed by Guyatt
5. Did the whole sample or a random selection of the sample, receive 
verification using a reference standard of diagnosis?
Not all before after studies evaluate a reference standard as the after 
test. Where the after test is not a recognised reference standard for the 
target disease full delineation of the impact of test errors requires 
evaluation of all study subjects with a reference standard.
6. Did patients receive the same reference standard regardless of the 
index test result?
Not addressed by Guyatt
7. Was the reference standard independent of the index test (the index 
test did not form part of the reference standard)?
Before after studies are concerned with evaluating the value of adding a 
test. Consequently the results of the before test are usually known at 
the time of interpreting the after test results. This item is therefore 
redundant for diagnostic before-after studies.
8. Was the execution of the index test described in sufficient detail to 
permit replication of the test?
Whether a diagnostic technology has therapeutic impact might depend 
on the physician using the test.
9. Was the execution of the reference standard described in sufficient 
detail to permit replication of the test?
10. Were the index test results interpreted without knowledge of the 
results of the reference standard?
To evaluate the technology's contribution to change in therapy 
therapeutic plans based on the 'before test' must be elicited before 
knowledge of the 'after test' results.
11. Were the reference standard results interpreted without knowledge 
of the results of the index test?
Before after studies are concerned with evaluating the value of adding a 
test. Consequently the results of the before test are usually known at 
the time of interpreting the after test results. However therapeutic plans 
based on the before test results should not be known at the time of 
making therapeutic plans based on a combination of the before and after 
test results. Before-after studies can be strengthened by an independent 
review of the after test's contribution to therapeutic decisions relative 
to the before test.
12. Were the same clinical data available when test results were 
interpreted as would be available when the test is used in practice?
The addition of a test may have appeared to have had an impact because 
of an incomplete pre-test work-up.
13. Were uninterpretatable/intermediate test results reported? Not addressed by Guyatt
14. Were withdrawals from the study explained? Bias may be introduced if the sample does not comprise consecutive 
patients presenting with a specific clinical problem
Additional methodological issues raised, specific to the 
outcome of 'therapeutic impact'
• Criteria for establishing therapeutic impact should be formulated a 
priori.Page 6 of 8
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narrative synthesis. Subsequently it has made us think
much more clearly about how we would define a refer-
ence standard for these types of studies in the future. For
example in the review discussed here the reference stand-
ard could have been defined as one or more of the follow-
ing:
• Medical history, physical examination, CT and/or MRI
• Medical history, physical examination, laboratory tests,
CT and/or MRI
• Medical history, physical examination, laboratory tests,
EEG, CT and/or MRI
This is an area where an improved checklist with a more
tightly worded question set would be more useful.
Our checklist did not allow us to capture sufficient detail
about patient spectrum. In this clinical area, the following
difficulties with patient spectrum became apparent:
• The date of presentation of the first episode does not
usually coincide with the onset of the condition because
the person could have had psychotic symptoms for years
without presenting to a health professional and often psy-
chosis has a gradual onset
• The duration of untreated psychosis is important
because it predicts response to treatment[12]
• A first episode could continue for ten years or more
without remission, even when the patient is having treat-
ment[13]
• The reason for referral of the patients into the study
could have been for clinical reasons, routine scanning on
admission or for research purpose
• The setting of the study (primary, secondary or tertiary
care) might be expected to yield different results
It is likely that the prevalence of space-occupying lesions
in each group would be different. A better checklist would
have provided more detail about the spectrum of included
patients.
The examples above illustrate that there is an overlap
between study characteristics and quality of the study and
that documentation of study characteristics is an impor-
tant element of quality assessment. Other issues that were
not assessed by our checklist included whether there was
an independent review of the diagnostic decisions and/or
treatment decisions made for each patient and whether
there was an appropriate sample size calculation
Conclusion
Evaluation of test accuracy is a component of test evalua-
tion distinct from diagnostic yield, therapeutic yield and
patient outcomes. We did not assess the test accuracy of
the new tests since CT and MRI scanning are accepted ref-
erence standards. In situations where the after test is not
an accepted reference standard, assessment of test accu-
racy would also be required. In fact, it is known that CT
does not have 100% sensitivity and specificity[2] so there
may have been some misclassification for false positives
and false negatives.
Guyatt[2] introduced the role of before and after studies
and their strengths and limitations. Some of the issues he
raised overlap to some extent with items on the QUADAS
checklist (see Table 2), even though QUADAS is aimed at
diagnostic accuracy as opposed to diagnostic and thera-
peutic yield studies. It can be seen from this table that
there are additional issues that Guyatt considered. How-
ever, as illustrated above, QUADAS does not capture all
pertinent issues either. Our attempts to modify QUADAS
addressed some but not all of these. The aim of this paper
is to start a process whereby an appropriate quality assess-
ment checklist can be developed and validated according
to established and accepted development procedures.
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